Overview

Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)

Status:
Recruiting

Trial end date:
2023-12-02

Target enrollment:

Participant gender:

Summary

This study evaluate possibility of brentuximab vedotin, administered after first treatment failure (no response or relapse after I line therapy) of Hodgkin's lymphoma, to induce durable response or cure without autologous stem cell transplantation.

Phase:

Phase 2

Details

Lead Sponsor:

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Treatments:

Antibodies, Monoclonal
Brentuximab Vedotin